« Return to News | CROs/Service Providers

OmniComm Inked 10 New Contracts

Friday, October 19, 2007 11:12 AM

Florida-based electronic data capture (EDC) provider OmniComm Systems inked 10 new contracts during the third quarter of 2007. The additional deals bring the company’s total contracts to 35 for the year.

Among the largest projects were a two-year phase III dermatology study enrolling more than 2,000 subjects at 100 sites and a two-year, anti-infective study with 500 subjects participating at 50 sites. The company cited the integration of Oracle Clinical with its EDC solution, TrialMaster, as being a critical factor in this year’s success.

The company also stated its CRO Preferred Program has brought in 17 CROs partnerships since April.

“CROs are enjoying the benefits of fixed pricing, no hidden costs or fees, a dedicated hosted environment and complete training and sales and marketing support, all distinct advantages of being an OmniComm partner,” said Stephen Johnson, executive vice president of business development.

OmniComm reported $1,076,000 in net sales during the third quarter of 2007 compared with $702,752 during the same period last year. However, it reported a net operating loss of $853,103 during the quarter compared with $759,945 last year.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.